Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of a vaginal insert containing tenofovir alafenamide and elvitegravir
PACTR202310819162115Phase 1Recruiting
- Sponsor
- CONRAD
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tenofovir alafenamide and elvitegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by CONRAD. Primary endpoint: Safety. Started Dec 2023; status: recruiting.
02
Drugs
tenofovir alafenamideelvitegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202310819162115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202310819162115.